Annexon is an early-stage biotech firm focused on developing treatments for inflammatory diseases. Its pipeline includes multiple drug candidates at varying stages of clinical development, such as Tanruprubart, a monoclonal antibody being tested for neurological conditions including Guillain-Barré syndrome and amyotrophic lateral sclerosis, as well as ANX007 for eye disease and ANX009 for kidney-related lupus complications. The company also has an oral medication candidate in earlier-stage testing for autoimmune disorders.

entry readiness 56 · MODERATE · exit proximity 0

Value area 3.48–5.42 · 86% of 120d volume overhead · heavy supply